CRNX Crinetics
- 37.350
- +0.870+2.38%
- 37.310
- -0.040-0.11%
Crinetics News
Crinetics Pharmaceuticals, Inc. (CRNX): The Biotech Stock With Biggest Upside Potential
While Crinetics Pharmaceuticals (NASDAQ:CRNX) Shareholders Have Made 75% in 3 Years, Increasing Losses Might Now Be Front of Mind as Stock Sheds 27% This Week
Oppenheimer Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $73
H.C. Wainwright Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $81
A Quick Look at Today's Ratings for Crinetics(CRNX.US), With a Forecast Between $55 to $92
Express News | Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Data 'Compelling' Despite Safety Concerns, Says Leerink
Crinetics Pharmaceuticals' Atumelnant Trial Data Prompts Hold Rating Amid Efficacy and Safety Concerns
Crinetics CAH Data 'Okay,' but Expectations Were High, Says Jefferies
Crinetics Shares Fall After Reporting 'Positive' Phase 2 Results for Congenital Adrenal Hyperplasia Treatment
Strong Buy Rating for Crinetics Pharmaceuticals Driven by Promising Atumelnant Data and Market Potential
Crinetics Pharmaceuticals Down Nearly 9%, on Pace for Largest Percent Decrease Since May 2022 -- Data Talk
Crinetics Announces Results From Phase 2 Trial of Atumelnant
Express News | Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (Cah)
Piper Sandler Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $97
Piper Sandler Keeps Their Buy Rating on Crinetics Pharmaceuticals (CRNX)
Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Crinetics Pharmaceuticals Strengthens Leadership With New Appointment
Crinetics Pharmaceuticals Analyst Ratings
No Data